Sampled TCR-Ts with good function was validated against a wide range of cells and the result showed specific cytotoxicity against relevant cancer cells expressing both HLA-A*02:01 and NY-ESO-1 antigen (Fig. 5f) and relevant peptide-enriched T2 cells or native T2 cells as negative control (Fig. 5h). The gene discussed is HLA-A; the disease is cancer.